Analysts have marginally raised their price target for Prothena from $13.00 to $13.00. They cited slight adjustments in discount rate and profit margin assumptions as drivers for the updated valuation.
What's in the News
- Special/Extraordinary Shareholders Meeting scheduled for November 19, 2025, at the offices of a&l goodbody llp, Dublin, Ireland (Key Developments).
- Results from the Phase 1 ASCENT clinical program in early symptomatic Alzheimer's disease were announced. PRX012 was identified as a potential once-monthly, subcutaneous anti-amyloid beta antibody with stable pharmacokinetics and low injection site reactions. However, higher ARIA-E rates were observed compared to approved therapies (Key Developments).
- Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR antibody based on recent findings (Key Developments).
- The company provided 2025 earnings guidance, estimating a net loss of $240 to $248 million. This is driven primarily by operational and investment activities, and significant non-cash expenses (Key Developments).
Valuation Changes
- Fair Value: The analyst fair value estimate remains unchanged at $13.00 per share.
- Discount Rate: The discount rate has risen slightly, from 7.19% to 7.25%.
- Revenue Growth: The projected revenue growth is nearly unchanged and is holding at approximately 109.9%.
- Net Profit Margin: Net profit margin has increased marginally, from 16.11% to 16.16%.
- Future P/E: The forward price-to-earnings ratio has decreased slightly, from 55.07x to 54.99x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.